Journal ArticleDOI
Anorectal melanoma: diagnosis and treatment.
TLDR
The history and current status of management of anorectal melanoma is reviewed, with a particular focus on surgical controversies and challenges in optimizing survival.Abstract:
An increase in the incidence of anorectal melanoma has recently been noted in the United States. Anorectal melanoma is an uncommon and lethal condition, with a median survival of <20 months. Unfortunately, nonspecific symptoms also attributable to common and benign conditions (eg, hemorrhoids) cause significant delay in its diagnosis. Although it has not been validated by clinical trials, abdominoperineal resection has historically been the treatment of choice for this disease. However, for the past 2 decades, a lack of clear survival benefit has led to a shift toward less-mutilating wide local excisions. Controversy still exists regarding the benefit of radiation therapy and chemotherapy. Furthermore, the value of nodal surgery in anorectal melanoma is unclear. In this article, we review the history and current status of management of anorectal melanoma, with a particular focus on surgical controversies and challenges in optimizing survival.read more
Citations
More filters
Journal ArticleDOI
Incidence, Surgical Treatment, and Prognosis of Anorectal Melanoma From 1973 to 2011: A Population-Based SEER Analysis.
TL;DR: This study provides an up-to-date estimation of the incidence and prognosis of AM by using SEER data and recommends surgery as the optimal treatment for local- and regional-stage AM patients but not for those with distant metastasis.
Journal ArticleDOI
Anal versus rectal melanoma: does site of origin predict outcome?
Danielle M. Bello,Elizabeth C Smyth,Daniel R. Perez,Shaheer Khan,Larissa K. Temple,Charlotte E. Ariyan,Martin R. Weiser,Richard D. Carvajal +7 more
TL;DR: The clinical relevance of location of origin of anorectal melanoma as a prognostic factor was examined with the use of a prospectively maintained database and outcomes were compared according to the site of origin.
Journal ArticleDOI
Anorectal mucosal melanoma.
Giulia Malaguarnera,Roberto Madeddu,Vito Emanuele Catania,Gaetano Bertino,Luca Morelli,Rosario Emanuele Perrotta,Filippo Drago,Michele Malaguarnera,Saverio Latteri +8 more
TL;DR: The treatment of advanced melanoma is evolving rapidly with better understanding of the disease biology and immunology, and considerable effort has been devoted to the identification of molecular determinants of response to target therapies and immunotherapy.
Journal ArticleDOI
Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases
Tristan J. Dodds,James S. Wilmott,Louise Jackett,Serigne Lo,Georgina V. Long,John F. Thompson,Richard A. Scolyer,Richard A. Scolyer +7 more
TL;DR: Poor responses of anorectal melanomas to immunotherapy may be caused by lower immunogenicity of these tumours as characterised by low mutation burden (and therefore low neoantigenicity), low TILs infiltrates and low PD-L1 expression.
Journal ArticleDOI
Extensive surgery and lymphadenectomy do not improve survival in primary melanoma of the anorectum: results from analysis of a large database (SEER)
TL;DR: Analysis of data obtained from a national representative database finds the prognostic value of positive loco‐regional lymph nodes and the impact of lymphadenectomy on overall survival are unclear.
References
More filters
Journal ArticleDOI
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
John M. Kirkwood,Myla Hunt Strawderman,Marc S. Ernstoff,Thomas J. Smith,Ernest C. Borden,Ronald H. Blum +5 more
TL;DR: IFN alpha-2b is the first agent to show a significant benefit in relapse-free and overall survival of high-risk melanoma patients in a randomized controlled trial.
Journal ArticleDOI
The National Cancer Data Base Report on Cutaneous and Noncutaneous Melanoma A Summary of 84,836 Cases from the Past Decade
TL;DR: This study reviews the case‐mix characteristics, management, and outcomes of melanoma cases occuring in the U. S. within the last decade.
Journal ArticleDOI
Rectal Cancer: Local Staging and Assessment of Lymph Node Involvement with Endoluminal US, CT, and MR Imaging—A Meta-Analysis
Shandra Bipat,Afina S. Glas,Frederik J. M. Slors,Aeilko H. Zwinderman,Patrick M.M. Bossuyt,Jaap Stoker +5 more
TL;DR: For local invasion, endoluminal US was most accurate and can be helpful in screening patients for available therapeutic strategies and shows better diagnostic accuracy than that of CT and MR imaging.
Journal ArticleDOI
High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190
John M. Kirkwood,Joseph G. Ibrahim,Vernon K. Sondak,Jon M. Richards,Lawrence E. Flaherty,Marc S. Ernstoff,Thomas J. Smith,Uma Rao,Mary Steele,Ronald H. Blum +9 more
TL;DR: The results of the intergroup E1690 trial demonstrate an RFS benefit of IFNalpha2b that is dose-dependent and significant for HDI by Cox multivariable analysis.
Journal ArticleDOI
Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma
TL;DR: A retrospective review of patients with melanoma treated at a single institution was undertaken to identify demographic factors associated with the development of clinically significant brain metastases and to determine the factors influencing the prognosis of this population to permit more informed recommendations regarding surgical therapy.